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ABSTRACT
Aims: Test the robustness of a linear regression transformation of semiquantitative
values from different Aβ tracers into a single continuous scale.
Short Research Article
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Study Design: Retrospective analysis.
Place and Duration of Study: PET imaging data acquired in Melbourne and Perth,
Australia, between August 2006 and May 2014.
Methodology: Aβ imaging in 633 participants was performed with four different
radiotracers: flutemetamol (n=267), florbetapir (n=195), florbetaben (n=126) and
NAV4694 (n=45). SUVR were generated with the methods recommended for each tracer,
and classified as high (Aβ+) or low (Aβ-) based on their respective thresholds. Linear
regression transformation based on reported head-to-head comparisons of each tracer
with PiB was applied to each tracer result.  Each tracer native classification was
compared with the classification derived from the transformed data into PiB-like SUVR
units (or BeCKeT: Before the Centiloid Kernel Transformation) using 1.50 as a cut-off.
Results: Misclassification after transformation to PiB-like SUVR compared to native
classification was extremely low with only 3/267 (1.1%) of flutemetamol, 1/195 (0.5%) of
florbetapir, 1/45 (2.2%) of NAV4694, and 1/126 (0.8%) of florbetaben cases assigned into
the wrong category. When misclassification occurred (<1% of all cases) it was restricted
to an extremely narrow margin (±0.02 BeCKeT) around the 1.50 BeCKeT threshold.
Conclusion: While a definitive transformation into centesimal units is being established,
application of linear regression transformations provide an interim, albeit robust, way of
converting results from different Aβ imaging tracers into more familiar PiB-like SUVR
units.
Keywords: Alzheimer’s disease; the Australian imaging biomarkers and lifestyle study of
ageing; Aβ imaging; dementia; centiloid.
ABBREVIATIONS
AD: Alzheimer’s disease
Aβ: β-amyloid
AIBL: Australian Imaging, Biomarkers, and Lifestyle study of ageing
PET: positron emission tomography
PiB: Pittsburgh compound B
FLUTE: flutemetamol
FBP: florbetapir
FBB: florbetaben
NAV: NAV4694
SUV: standardized uptake value
SUVR: Standardized uptake value ratio
BeCKeT: Before the Centiloid Kernel Transformation
Aβ+: “high” Aβ burden
Aβ-: “low” Aβ burden
1. INTRODUCTION
Aβ imaging with PET allows accurate detection of Alzheimer’s disease (AD) pathology in
those neurodegenerative conditions where Aβ plays a role [1]. Aβ imaging also provides
unique information on the relationship between brain Aβ and different cognitive parameters
as well as genetic, central nervous system or peripheral markers [2]. Researchers often
validate their assessments against the amount of Aβ in the brain. Most researchers are
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familiar with the 11C-PiB spectrum of SUVR values, and what PiB SUVR constitutes a “high”
or “low” Aβ burden.
The introduction of novel F-18 labeled Aβ imaging with their different kinetics and
recommended quantification procedures as well as different autopsy-validated SUVR
thresholds to determine “high” and “low” Aβ burden, [3-10] highlighted the need to
standardize all these results and display them along a single universal scale. A recent
publication reports on a three-tracer (PiB, florbetapir and flutemetamol) comparison where,
despite having different pharmacodynamic behavior, different quantitative ranges and
different degrees of white matter retention, yielded highly correlated and consistent results
between them [11]. There is an international effort to establish this single scale under the
name of Centiloid [12]. The Centiloid project proposes to perform head-to-head comparison
between PiB and all the different Aβ tracers in both young and elderly as well as Alzheimer’s
disease patients, aimed at covering the whole spectrum of Aβ deposition. While the Centiloid
is established and implemented, large cohort studies like the Australian Imaging,
Biomarkers, and Lifestyle (AIBL) study of ageing require both categorical and continuous
variables of brain Aβ burden in order to validate biomarker results right now. This cross-
validation is crucial for biomarker discovery and being able to display in the same continuous
scale estimates of Aβ burden generated using different Aβ imaging radiotracers increases
the sample size and the robustness of the findings. Therefore, a linear regression approach
to transform the results of each Aβ tracer generated with their own validated quantification
method into PiB-like units was adopted.
The purpose of this study was to test the robustness of such linear regression
transformations.
2. MATERIALS AND METHODS
Aβ imaging in 633 participants was performed with four different radiotracers: 18F-
flutemetamol (FLUTE), 18F-florbetapir (FBP), 18F-florbetaben (FBB), and 18F-NAV4694
(NAV). Written informed consent was obtained from all participants. Approval for the study
was obtained from the Austin Health, St. Vincent’s Hospital, Edith Cowan University and
Hollywood Private Hospital Human Research Ethics Committees. Participants included in
the study underwent positron emission tomography (PET) examinations in either Melbourne
or Perth between August 2006 and May 2014. While those participants that underwent FBB
PET were enrolled in the Women Healthy Ageing Project (WHAP), the majority of
participants were enrolled into the longitudinal AIBL study of ageing which has been
described in detail elsewhere [13,14].
Aβ imaging with positron emission tomography (PET) was conducted using either FBP,
FLUTE, FBB or NAV. Two hundred and sixty-seven participants underwent FLUTE imaging,
195 participants underwent FBP, 126 participants were scanned with FBB, and 45 with NAV.
PET methodology for each tracer has previously been described in detail [3,5,6,10]. A 20-
minute acquisition was performed 40 minutes post-injection of NAV, 50 minutes post-
injection of FBP and 90 minutes post-injection of FLUTE and FBB. For semiquantitiative
analysis, a volume of interest template was applied to the summed and spatially normalized
PET images in order to obtain standardized uptake value (SUV). The images were then
scaled to the SUV of each tracer recommended reference region to generate a tissue ratio
termed SUV ratio (SUVR). A Global measure of Aβ burden was computed using the mean
SUVR in the frontal, superior parietal, lateral temporal, occipital and anterior and posterior
cingulate regions of the brain. For this analysis, NAV and FBB SUV images data were
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normalized to the cerebellar cortex [3,10]. As advocated by the respective pharmaceutical
company, the whole cerebellum was the reference region for FBP [4] while for FLUTE the
reference region was the pons [8]. In the current study, the SUVR index was also considered
as a dichotomous variable. The results generated with the tracer-specific methods were
classified as “high” (Aβ+) or “low” (Aβ-) based on each radiotracer neuropathologically
validated threshold [7,8,10]. Participants who underwent FBP were considered Aβ+ when
SUVR ≥1.11 [7], for FLUTE when SUVR ≥0.62 [8], for FBB when SUVR ≥1.45, [15] for NAV
when SUVR ≥1.50 [10] (Table 1).
A linear regression transformation, adapted from reported head-to-head comparisons of
each of the tracers with PiB [6,9,10,16] was applied to the respective Aβ tracer SUVR to
transform it into a “PiB-like” SUVR unit. Acknowledging the ongoing work aimed at
establishing a single universal centesimal scale for all Aβ tracers (Centiloid) [12], these “PiB-
like” SUVR were termed BeCKeT (Before the Centiloid Kernel Transformation). As with PiB,
a BeCKeT ≥1.50 was classified as Aβ+ [14]. To assess the goodness of the transformation,
discordant classification ratios were generated from the comparison between each tracer
native categorical classification and the classification derived from the respective
transformed data into BeCKeT. Statistical evaluations were performed using a Tukey-
Kramer HSD test to establish differences between cohorts. Categorical differences were
evaluated using Fisher’s exact test.
3. RESULTS AND DISCUSSION
The demographic characteristics of the participants studied with each radiotracer are
detailed in Table 1. A total of 568 of 633 (90%) participants underwent PET imaging in
Melbourne while 65 participants (10%) were scanned in Perth.
Participants enrolled in WHAP, studied with FBB, were significantly younger and the
prevalence of Aβ+ was lower than in those subjects who underwent FLUTE, FBP and NAV
(Table 1). The intercept, slope and correlation coefficient for each Aβ tracer is also detailed
in Table 1.
Misclassification after transformation to PiB-like SUVR compared to native classification was
extremely low, with only 6/633 (0.9%) of all cases -3/267 (1.1%) of FLUTE, 1/195 (0.5%) of
FBP, 1/126 (0.8%) of FBB and 1/45 (2.2%) of NAV cases- assigned into the wrong category
(Table 1). Moreover, all six Aβ- cases were misclassified as Aβ+, and not the other way
around. When this misclassification occurred it was restricted to an extremely narrow margin
around the 1.50 BeCKeT threshold. In other words, if values falling above or below 0.02
BeCKeT around the 1.50 threshold (1.48-1.52) were discarded, the agreement between
native SUVR and BeCKeT would be 100% for all tracers.
Despite using different reference regions and presenting with different pharmacokinetics and
different dynamic SUVR ranges, (Fig. 1) all F-18 Aβ imaging radiotracers are highly
correlated with PiB [6, 9-11, 16]. Given the disparity in analytical methods and resulting
SUVR for the different F-18 labelled Aβ tracers, we aimed at transforming the respective
native SUVR into a PiB-like spectrum of continuous values applying a linear regression
analysis to the results of more than 600 Aβ PET studies with four different Aβ tracers: FBP,
FLUTE, FBB and NAV (Fig. 1). The dichotomous classification into Aβ+ and Aβ- was
essentially the same, with less than 1% discrepancy when using native SUVR or BeCKeT,
suggesting that BeCKeT can be used in biomarker discovery and validation until the
Centiloid scale can be implemented. Another relevant aspect of this approach is that after
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the transformation there is a common threshold to distinguish high or low Aβ burden across
tracers, (Fig. 1) where the combination of results from independent samples allows
validation or discovery of genetic, cognitive or fluid markers or parameters in a large number
of individuals in order to see if the findings are robust to be translated into clinical practice.
Furthermore, as accurately pointed out recently [11], the selection of the cut-off value will
depend on the needs of the study, either using a lower cut-off to increase sensitivity or a
higher one to increase specificity.
Fig. 1. A common scale and threshold for all Aβ tracers
All available Aβ radiotracers, due to their intrinsic pharmacological and pharmacokinetic
characteristics, as well as their recommended analytical methods yield semiquantitative statements of
Aβ burden in their own range of values and their particular thresholds. In order to render all this diverse
spectra of native SUVR into a single continuous scale (BeCKeT), a linear regression transformation
was applied to each radiotracer: FLUTE (BeCKeTFLUTE=2.3529xFLUTE SUVRpons+0.0802), FBP
(BeCKeTFBP=1.6667xFBP SUVRwcb -0.33), FBB (BeCKeTFBB=1.32xFBB SUVRcbctx -0.3418), and NAV
(BeCKeTNAV=1.02656xNAV SUVRcbctx -0.0128). When the native categorical classification into Aβ- or
Aβ+ for each radiotracer was compared with the classification resulting from the BeCKeT
transformation, there were no significant differences (P=1.00) between them, with discrepancy being
less than 1%
Table 1. Demographics, transformation parameters and results for four different F-18
Aβ tracers
FLUTE FBP FBB NAV
n 267 195 126 45
Age 74.4 ± 5.9 74.0 ± 6.2 69.3 ± 2.6* 73.6 ± 8.4
Gender (m/f) 122/145 84/111 0/126* 22/23
Aβ status (%Aβ+)
(based on native SUVR)
32% 21% 10%* 36%
Reference region pons whole cb cb cortex cb cortex
Cut-off 0.62 [8] 1.11 [7] 1.42 [16] 1.50 [10]
Reported correlation with PiB R2=0.85 [6] R2=0.94 [9] R2=0.94 [16] R2=0.98 [10]
Native SUVR range 0.35 - 1.05 0.70 - 1.70 0.95 – 2.10 1.04 - 3.16
Intercept 0.08 -0.33 -0.342 -0.013
Slope 0.43 0.6 0.76 0.97
Discordant classification
(after BeCKeT transformation)
3/267 (1.1%) 1/195(0.5%) 1/126 (0.8%) 1/45 (2.2%)
*Significantly different from FLUTE, FBP and NAV cohorts (P = 0.05)
Abbreviations: FLUTE: flutemetamol; FBP: florbetapir; FBB: florbetaben; NAV: NAV4694; SUVR: Standardized
uptake value ratio; cb: cerebellum; PiB: Pittsburgh compound B; Aβ-: low Aβ burden; Aβ+: high Aβ burden
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There are limitations in this approach. For example, the linear transformation is based on
comparison of elderly individuals that might already have some degree of Aβ deposition,
therefore a true “0” for the scale cannot reliably be established. As proposed by the Centiloid
project, lack of Aβ deposition is almost certain in young individuals, and their Aβ imaging
results will provide a robust “0” for the scale. Another limitation is that a couple of linear
regression transformations were derived from limited datasets. It might be possible that
those parameters cannot be generalized to other, much larger groups.
4. CONCLUSION
Despite the aforementioned limitations, BeCKeT provide an interim and robust way of
transforming SUVR results from different Aβ imaging tracers into more familiar PiB-like
SUVR units, but most importantly, allowing integration into a single scale semiquantitative
data obtained from different Aβ tracers.
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